论文部分内容阅读
阿罗洛尔(Arotinolol)是一种新型非选择性亲水性β-阻滞剂。本文研究15例特发性震颤(ET)患者,全部接受Arotinolol每天30mg,分3次给药,共8周。15例患者在用药2周内,姿态和运动震颤均有主客观改善。本品对心血管系统、舒张压和脉搏均有显著降低(p<0.01)。姿态震颤的振幅(自平均450μV降到平均170μV,p<0.001)显著降低,平均降低43％。本品对运动震颤亦有效。全部患者均未发生中枢神经系统副作用。本文研究显示,每天口服Arotinolol30mg对所有ET患者的姿态和运动震颤均有改善。业已证明心得安对治疗ET有效,但
Arotinolol is a new non-selective hydrophilic β-blocker. In this paper, 15 patients with idiopathic tremor (ET) were enrolled. All received 30 mg Arotinolol daily for 3 weeks for 8 weeks. 15 patients in the medication within 2 weeks, posture and motor tremor both subjective and objective improvements. This product on the cardiovascular system, diastolic blood pressure and pulse were significantly lower (p <0.01). The amplitude of attitude tremor (from an average of 450 μV down to an average of 170 μV, p <0.001) was significantly lower with an average reduction of 43%. This product is also effective tremor. All patients had no central nervous system side effects. This study shows that daily oral Arotinolol 30mg improved posture and motor tremor in all patients with ET. It has been shown that propranolol is effective in treating ET but